

#### 9h00 – Abertura do secretariado

#### 10h00 – 10h45 | Imagiologia e Medicina Nuclear

**Moderação:** *Dra. Ana Paula Vasconcelos, CHLO e Dr. José Carlos Marques, IPO Lisboa*

#### Supplemental Breast MRI for Women with Extremely Dense Breasts: Results of the Second Screening Round of the DENSE.

*Veenhuizen S, V. de Lange S, Bakker M., et al. Radiology. 2021 May; 299 (2): 278–286 <https://doi.org/10.1148/radiol.2021203633>.*

**Dr. João Abrantes, CHTMAD**

#### Contrast enhanced mammography (CEM) versus magnetic resonance imaging (MRI) for staging of breast cancer: The pro CEM perspective

*M.B.I. Lobbes, E.M. Heuts, M. Moosdorff, T.J.A. van Nijnatten. European Journal of Radiology 202 July; 142: 1-7. <https://doi.org/10.1016/j.ejrad.2021.109883>*

**Dr. William Schmitt, CHUP**

Discussão – 15 minutos

#### 10h45 – 11h30 | Patologia

**Moderação:** *Prof. Dr. Fernando Schmitt, IPATIMUP e Dra. Teresa Simões, CHUC*

#### Denkert, C., Seither, F., Schneeweiss, A., Link, T., Blohmer, J. U., Just, M., ... & Loibl, S. (2021). Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.

*The Lancet Oncology, 22(8), 1151-1161.*

**Dr. Daniel Gomes Pinto, CHLO**

#### Ai, D., Yao, J., Yang, F., Huo, L., Chen, H., Lu, W., ... & Ding, Q. (2021). TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.

*Modern Pathology, 34(4), 710-719.*

**Dra. Fátima Ramalhosa, CHUC**

Discussão – 15 minutos

#### 11h30 – 11h45 – Intervalo

#### 11h45 – 12h30 | Cirurgia

**Moderação:** *Dr. David Pinto, Fundação Champalimaud e Dr. João Vargas Moniz, IPO Lisboa*

#### The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis

*Parinita K Swarnkar, Salim Taye, Michael J Michell and Kefah Mokbel. Cancers 2021, 13(7), 1539; <https://doi.org/10.3390/cancers13071539>.*

**Dra. Cristina Costa, IPO Lisboa**

#### Benefits of Surgical Treatment of Stage IV Breast Cancer for Patients With Known Hormone Receptor and HER2 Status

*Kelly Stahl, William Wong, Daleela Dodge, Ashton Brooks, Christopher McLaughlin, Elizabeth Olecki, Joseph Lewcun, Kristina Newport, Monali Vasekar and Chan Shen. Ann Surg Oncol 2021 May;28(5):2646-2658. doi: 10.1245/s10434-020-09244-5*

**Dr. André Magalhães, CHUSJ**

Discussão – 15 minutos

#### 12h30 -13h15 – Apresentação Estudo:

**Impacto económico e psicossocial do Cancro da mama em Portugal da LPCC**  
**Dra. Sónia Silva e Dra. Natália Amaral, LPCC**

#### 13h15 – 14h30 – Almoço

#### 14h30 – 15h15 | Terapêutica Sistémica – Doença precoce

**Moderação:** *Dra. Gabriela Sousa, IPO Coimbra e Prof. Dr. José Luís Passos Coelho, Hospital Da Luz*

**Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer**  
*N Engl J Med 2021; 385:2336-2347, DOI: 10.1056/NEJMoa2108873*

**Dr. Diogo Branco, Institut Jules Bordet**

**Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer**

*N Engl J Med 2021;384:2394-405. DOI: 10.1056/NEJMoa2105215*

**Prof. Dr. Miguel Abreu, IPO Porto**

#### 15h15-16h00 | Terapêutica Sistémica – Doença Avançada

**Moderação:** *Dra. Susana Sousa, IPO Porto e Dr. Paulo Cortes, Hospital Lusíadas Lisboa*

**Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355)**

*Lancet 2020; 396: 1817–28 (December 5, 2020)*

**Dr. Miguel Barbosa, CHUSJ**

**DESTINY-Breast03: Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Previously Treated HER2+ Metastatic Breast Cancer: subgroup analyses**

*GS3-01, SABCs 2021*

**Dra. Rita Garcia, IPO Coimbra**

#### 16h00 – 16h15 – Intervalo

#### 16h15 – 17h00 | Radioncologia

**Moderação:** *Dra. Helena Pereira, IPO Porto e Dra. Margarida Borrego, CHUC*

**Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.**

*Philip M Poortmans, Caroline Weltens, Catherine Fortpied, Carine Kirkove et al for the European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups; Lancet Oncol 2020; 21: 1602–10; DOI: 10.1016/S1470-2045(20)30472-1*

**Dr. André Laranja, IPO Porto**

**European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer.**

*Icro Meattini, Carlotta Becherini, Liesbeth Boersma, et al. Lancet Oncol 2022; 23: e21–31; doi: 10.1016/S1470-2045(21)00539-8*

**Dr. Pedro Meireles, CHUSJ**

Discussão – 15 minutos

#### 17h30 – Assembleia Geral da SPS